Interstitial pneumonia following administration of pegfilgrastim during carboplatin and etoposide chemotherapy for small‑cell lung cancer

Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol. 24:3187–3205. 2006. View Article : Google Scholar : PubMed/NCBI

Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, et al: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 47:8–32. 2011. View Article : Google Scholar : PubMed/NCBI

Kosaka Y, Rai Y, Masuda N, Takano T, Saeki T, Nakamura S, Shimazaki R, Ito Y, Tokuda Y and Tamura K: Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer. 23:1137–1143. 2015. View Article : Google Scholar : PubMed/NCBI

Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T, Shibata T, Kunitoh H, Tamura T and Saijo N: Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 97:162–169. 2007. View Article : Google Scholar : PubMed/NCBI

Yamamoto N, Sekine I, Nakagawa K, Takada M, Fukuoka M, Tanigawara Y and Saijo N: A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia. Jpn J Clin Oncol. 39:425–430. 2009. View Article : Google Scholar : PubMed/NCBI

Lee KH, Kim JY, Lee MH, Han HS, Lim JH, Park KU, Park IH, Cho EK, Yoon SY, Kim JH, et al: A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09. Support Care Cancer. 24:1709–1717. 2016. View Article : Google Scholar : PubMed/NCBI

Masuda N, Tokuda Y, Nakamura S, Shimazaki R, Ito Y and Tamura K: Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: A randomized controlled trial. Support Care Cancer. 23:2891–2898. 2015. View Article : Google Scholar : PubMed/NCBI

Yang BB, Morrow PK, Wu X, Moxness M and Padhi D: Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: On-body injector and manual injection with a prefilled syringe. Cancer Chemother Pharmacol. 75:1199–1206. 2015. View Article : Google Scholar : PubMed/NCBI

Matthews JH: Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin's disease: Possible synergy. Lancet. 342:9881993. View Article : Google Scholar : PubMed/NCBI

Yokose N, Ogata K, Tamura H, An E, Nakamura K, Kamikubo K, Kudoh S, Dan K and Nomura T: Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma. Br J Cancer. 77:2286–2290. 1998. View Article : Google Scholar : PubMed/NCBI

Ruiz-Argüelles GJ, Arizpe-Bravo D, Sánchez-Sosa S, Rojas-Ortega S, Moreno-Ford V and Ruiz-Argüelles A: Fatal G-CSF-induced pulmonary toxicity. Am J Hematol. 60:82–83. 1999. View Article : Google Scholar : PubMed/NCBI

Adachi K, Suzuki M, Sugimoto T, Yorozu K, Takai H, Uetsuka K, Nakayama H and Doi K: Effects of granulocyte colony-stimulating factor (G-CSF) on bleomycin-induced lung injury of varying severity. Toxicol Pathol. 31:665–673. 2003. View Article : Google Scholar : PubMed/NCBI

Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M, et al: Interstitial lung disease in Japanese patients with lung cancer: A cohort and nested case-control study. Am J Respir Crit Care Med. 177:1348–1357. 2008. View Article : Google Scholar : PubMed/NCBI

Niitsu N, Iki S, Muroi K, Motomura S, Murakami M, Takeyama H, Ohsaka A and Urabe A: Interstitial pneumonia in patients receiving granulocyte colony-stimulating factor during chemotherapy: Survey in Japan 1991–96. Br J Cancer. 76:1661–1666. 1997. View Article : Google Scholar : PubMed/NCBI